Director Greenleaf (PTHS) awarded 25,478 Pelthos Therapeutics RSUs
Rhea-AI Filing Summary
Greenleaf Peter reported acquisition or exercise transactions in this Form 4 filing.
Pelthos Therapeutics Inc. director Peter Greenleaf reported an award of 25,478 shares of Common Stock, received as a grant of restricted stock units under the company’s 2023 Equity Incentive Plan. The award was granted as compensation for his service on the board of directors, at a stated price of $0.00 per share.
The RSUs vest over time: one-third of the underlying shares vested on July 2, 2025, with the remaining shares vesting in equal quarterly installments over the following two years, subject to continued service. Following this grant, Greenleaf directly holds 25,478 shares of Common Stock from this award.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 25,478 shares
Net Buy
1 txn
Insider
Greenleaf Peter
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 25,478 | $0.00 | $0.00 |
Holdings After Transaction:
Common Stock — 25,478 shares (Direct)
Footnotes (2)
- F1. Represents shares of common stock, par value $0.0001 per share ("Common Stock") of Pelthos Therapeutics Inc. (the "Issuer"), issuable upon settlement of restricted stock units of the Issuer ("RSUs") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the "2023 Plan"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4 filed by the reporting person (the "Original Form 4"). This Form 4 amendment (this "Amendment") is being filed to amend the Original Form 4 in order to report the grant of such RSUs in Table I.
- F2. The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest as follows: the initial one-third of shares vested on July 2, 2025, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two years, so long as the reporting person remains in the service of the Issuer on each such anniversary.
Key Figures
RSU grant size: 25,478 shares
Grant price: $0.00 per share
Holdings after transaction: 25,478 shares
+2 more
5 metrics
RSU grant size
25,478 shares
Restricted stock units representing Common Stock granted to director
Grant price
$0.00 per share
Stated price for RSU-related Common Stock in the award
Holdings after transaction
25,478 shares
Total Common Stock directly held by Greenleaf after the grant
Initial vesting date
July 2, 2025
One-third of RSU shares vest on this date
Vesting period
Two years
Remaining RSUs vest quarterly over this period after initial vesting
Key Terms
restricted stock units, 2023 Equity Incentive Plan, Form 4 amendment, board of directors, +1 more
5 terms
restricted stock units financial
"issuable upon settlement of restricted stock units of the Issuer ("RSUs") granted to the reporting person"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
2023 Equity Incentive Plan financial
"RSUs granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time"
Form 4 amendment regulatory
"This Form 4 amendment (this "Amendment") is being filed to amend the Original Form 4"
board of directors financial
"received as compensation for the reporting person's service as a member of the Issuer's board of directors"
The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.
vesting financial
"The RSUs vest as follows: the initial one-third of shares vested on July 2, 2025, and the remainder vesting in equal installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Pelthos Therapeutics (PTHS) director Peter Greenleaf report in this Form 4/A?
Peter Greenleaf reported receiving an award of 25,478 restricted stock units converting into Common Stock. The grant was made under Pelthos Therapeutics’ 2023 Equity Incentive Plan as compensation for his service on the company’s board of directors.
At what price were Peter Greenleaf’s Pelthos Therapeutics (PTHS) RSUs granted?
The RSUs reported in the Form 4/A have a stated price of $0.00 per share. This reflects that they are a compensation grant, not shares bought for cash; value to Greenleaf depends on future stock price and vesting of the award.
What is the vesting schedule for Peter Greenleaf’s Pelthos Therapeutics (PTHS) RSUs?
The RSUs vest over roughly two years. One-third of the underlying shares vested on July 2, 2025, with the remaining shares vesting in equal quarterly installments, so long as Greenleaf continues serving Pelthos Therapeutics as a director.
Why were the Pelthos Therapeutics (PTHS) RSUs originally reported in Table II and now amended?
The original Form 4 reported the RSUs in Table II for derivative securities. This amendment moves the grant into Table I by showing the underlying common shares issuable upon settlement, clarifying how the RSUs translate into Pelthos Therapeutics Common Stock.